ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Zogenix acquires rare disease start-up Modis for $250 million

by Rick Mullin
August 30, 2019 | APPEARED IN VOLUME 97, ISSUE 34

 

Zogenix, an Emeryville, California–based rare-disease therapy specialist, will pay $250 million to acquire Modis Therapeutics, a start-up focused on rare genetic diseases. Modis’s lead candidate is MT1621, a deoxynucleoside substrate enhancement therapy in late-stage development for the treatment of thymidine kinase 2 deficiency, an often fatal mitochondrial DNA depletion disorder that primarily affects children. Modis was formed in 2016 and raised $30 million in series A funding less than a year ago.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment